VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
PRICE: 0 CENTS
Stevanato Group S.p.A.
STVN · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Stevanato Group S.p.A. provides primary packaging, ready-to-use systems, drug delivery components, diagnostics consumables, and engineering equipment for injectable drug and life-science manufacturing. The moat is strongest in high-value solutions, where regulatory qualification, proprietary process know-how, trusted quality systems, and EZ-fill compatibility support premium pricing. Q1 2026 revenue mix shows high-value solutions at about 47% of revenue, while FY2025 revenue from GLP-1 applications reached roughly 19% to 20% of company revenue. Other containment and delivery remains more competitive but sticky through qualification and supply contracts. Engineering adds service and cross-selling value, though weak order intake has lowered its current mix.
Primary segment
High-Value Solutions
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
3 segments · 7 tags
Updated 2026-05-27
Segments
High-Value Solutions
High-value primary packaging and integrated solutions for injectable drugs
Revenue
47%
Structure
Oligopoly
Pricing
strong
Share
—
Peers
Other Containment and Delivery Solutions
Standard primary packaging and related services for injectable drugs and diagnostics
Revenue
44%
Structure
Competitive
Pricing
weak
Share
—
Peers
Engineering
Pharmaceutical production, inspection, assembly, packaging/serialization and glass converting equipment
Revenue
9%
Structure
Competitive
Pricing
moderate
Share
—
Peers
—
Moat Claims
High-Value Solutions
High-value primary packaging and integrated solutions for injectable drugs
Revenue_share is computed from Q1 2026 Form 6-K revenue disaggregation: EUR 128.614m high-value solutions out of EUR 273.574m total revenue. FY2025 Form 20-F showed high-value solutions reached EUR 546.374m, or 46.0% of total revenue, up from 38.3% in FY2024. Key glass tube suppliers disclosed in the 2025 Form 20-F include Schott, NEG, Nipro, and Corning.
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
Primary packaging is part of the drug product and regulatory filings; changing suppliers requires customer re-qualification and time.
Erosion risks
- Dual-sourcing reduces lock-in
- Competing container formats/materials (polymer, alternative delivery)
- Major customers use purchasing leverage
Leading indicators
- Share of customer programs using Stevanato RTU formats
- Churn/qualification losses on new molecule wins
- Gross margin and price/mix in high-value portfolio
Counterarguments
- Large pharma can and does qualify multiple suppliers
- Competitors can replicate performance features with enough time and capex
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
High-value products rely on proprietary processes and specialized manufacturing; scale/capacity investments support innovation and delivery reliability.
Erosion risks
- Competitor capacity additions narrow supply tightness
- Process innovations diffuse over time
- Execution risk in ramping new plants/lines
Leading indicators
- Yield/scrap and customer complaint rates
- On-time delivery and capacity utilization at new sites
- R&D output (new platforms) and adoption
Counterarguments
- Large competitors can invest comparable capex and hire expertise
- Customer specs may standardize, reducing differentiation
De Facto Standard
Network
De Facto Standard
Strength
Durability
Confidence
Evidence
EZ-Fill ready-to-use systems are designed to be compatible with existing fill-finish lines; broad installed compatibility supports adoption inertia.
Erosion risks
- Alternative RTU standards from rivals gain adoption
- Equipment upgrades reduce compatibility advantage
Leading indicators
- Installed base of lines qualified for Stevanato RTU formats
- Share of RTU vs bulk formats in customer demand
Counterarguments
- Industry standard language is self-assessed; rivals also offer RTU platforms
- Fill-finish OEMs can support multiple RTU formats
Brand Trust
Demand
Brand Trust
Strength
Durability
Confidence
Evidence
In regulated injectable supply chains, long track record, reliability, and audited quality systems support preferred-supplier status.
Erosion risks
- Quality incidents/recalls damage reputation
- New entrants with strong QA win share
- Customer diversification away from single suppliers
Leading indicators
- Audit findings and recall/complaint metrics
- Top-customer retention and new molecule wins
- Net promoter / preferred supplier status (if disclosed)
Counterarguments
- Reputation can shift quickly after quality issues
- Big pharma will still pressure price even with trusted suppliers
Other Containment and Delivery Solutions
Standard primary packaging and related services for injectable drugs and diagnostics
Revenue_share is computed from Q1 2026 Form 6-K revenue disaggregation: EUR 120.347m other containment and delivery solutions out of EUR 273.574m total revenue. FY2025 Form 20-F showed other containment and delivery revenue declined to EUR 491.800m from EUR 511.391m in FY2024. Key glass tube suppliers disclosed in the 2025 Form 20-F include Schott, NEG, Nipro, and Corning.
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
Even for more standard components, regulatory filings and qualification create switching friction and favor incumbent suppliers.
Erosion risks
- Standard components commoditize
- Customers qualify multiple suppliers
Leading indicators
- Customer concentration and multi-sourcing trends
- Pricing vs raw material inflation pass-through
Counterarguments
- Commodity products are easier to dual-source than specialized platforms
Long Term Contracts
Demand
Long Term Contracts
Strength
Durability
Confidence
Evidence
Multi-year master supply agreements and drug-life-cycle purchasing patterns provide revenue stability and reduce spot competition.
Erosion risks
- Contract renegotiations in downturns
- Customer destocking/inventory cycles
Leading indicators
- Backlog level and book-to-bill
- Renewal/price reset outcomes
Counterarguments
- Large customers can renegotiate pricing at renewal and shift volumes
Operational Excellence
Supply
Operational Excellence
Strength
Durability
Confidence
Evidence
Consistent global quality systems and high audit frequency support reliability and lower total cost of ownership for customers.
Erosion risks
- Quality failures reduce differentiation
- Rivals match QA and automation
Leading indicators
- Complaint rate, rejects, and on-time delivery
- Gross margin vs peers in commodity categories
Counterarguments
- Most credible suppliers in this industry run strong QA systems; excellence may not be unique
Engineering
Pharmaceutical production, inspection, assembly, packaging/serialization and glass converting equipment
Revenue_share is computed from Q1 2026 Form 6-K revenue disaggregation: EUR 24.613m engineering revenue out of EUR 273.574m total revenue. FY2025 Form 20-F showed engineering revenue declined to EUR 148.108m from EUR 170.294m in FY2024, and Q4 FY2025 materials flagged weak order intake and slower opportunity conversion.
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Installed base of equipment drives recurring after-sales revenue (maintenance, spare parts, optimization, upgrades).
Erosion risks
- Third-party service providers capture service work
- Customers internalize maintenance capabilities
Leading indicators
- After-sales revenue mix within Engineering
- Installed base growth and service attach rates
Counterarguments
- Equipment buyers can multi-source service and spare parts depending on contract terms
Capex Knowhow Scale
Supply
Capex Knowhow Scale
Strength
Durability
Confidence
Evidence
Specialized know-how in GMP-compliant automation, inspection (incl. AI), and precision glass forming lines; project-based delivery capabilities matter.
Erosion risks
- Competing OEMs match features (AI inspection, modular lines)
- Project execution overruns hurt reputation
Leading indicators
- Backlog conversion and project margins
- Win rates on complex inspection/assembly programs
Counterarguments
- Automation/inspection markets have many capable vendors and rapid tech diffusion
Scope Economies
Supply
Scope Economies
Strength
Durability
Confidence
Evidence
Bundled offering across primary packaging + equipment + services enables cross-selling and one-stop-shop value proposition for customers.
Erosion risks
- Customers prefer best-of-breed point solutions
- Internal re-org disrupts cross-selling
Leading indicators
- Attach rate of equipment in accounts that buy packaging
- Engineering backlog sourced from existing packaging customers
Counterarguments
- Many customers separate equipment procurement from packaging sourcing to avoid vendor lock-in
Evidence
included as part of the regulatory filings required before commercialization
Regulatory integration raises switching costs and extends qualification cycles.
changing providers can be a lengthy process
Company describes time costs to change providers, supporting qualification-driven stickiness.
unique set of proprietary manufacturing processes
Signals process know-how and manufacturing capability as a barrier to entry.
we enjoy premium pricing
Premium pricing is consistent with differentiated products supported by know-how/capex.
industry standard for ready-to-fill vials and cartridges
Company asserts standard-like positioning and cites broad fill-finish line compatibility.
Showing 5 of 13 sources.
Risks & Indicators
Erosion risks
- Dual-sourcing reduces lock-in
- Competing container formats/materials (polymer, alternative delivery)
- Major customers use purchasing leverage
- Competitor capacity additions narrow supply tightness
- Process innovations diffuse over time
- Execution risk in ramping new plants/lines
Leading indicators
- Share of customer programs using Stevanato RTU formats
- Churn/qualification losses on new molecule wins
- Gross margin and price/mix in high-value portfolio
- Yield/scrap and customer complaint rates
- On-time delivery and capacity utilization at new sites
- R&D output (new platforms) and adoption
Research STVN elsewhere
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.